keyword
MENU ▼
Read by QxMD icon Read
search

breast cancer chemotherapy

keyword
https://www.readbyqxmd.com/read/29458045/aldose-reductase-inhibitor-fidarestat-prevents-doxorubicin-induced-endothelial-cell-death-and-dysfunction
#1
Himangshu Sonowal, Pabitra Pal, Kirtikar Shukla, Ashish Saxena, Satish K Srivastava, Kota V Ramana
Despite doxorubicin (Dox) being one of the most widely used chemotherapy agents for breast, blood and lung cancers, its use in colon cancer is limited due to increased drug resistance and severe cardiotoxic side effects that increase mortality associated with its use at high doses. Therefore, better adjuvant therapies are warranted to improve the chemotherapeutic efficacy and to decrease cardiotoxicity. We have recently shown that aldose reductase inhibitor, fidarestat, increases the Dox-induced colon cancer cell death and reduces cardiomyopathy...
February 16, 2018: Biochemical Pharmacology
https://www.readbyqxmd.com/read/29457953/from-nurse-to-service-user-a-personal-cancer-narrative
#2
Anneyce Knight
This article presents a snapshot of my experience of being a nurse who became a service user with breast cancer. It begins by outlining the Humanization of Healthcare Framework ( Todres et al, 2009 ), which is a values-based context that can be used to underpin daily care. Generic applications for each of the dimensions of the framework are suggested. This framework is then used to contextualise my experience of receiving my diagnosis and the ensuing chemotherapy. Using examples from my personal narrative, I make some recommendations for 'small actions' that can contribute to more humanised and person-centred care...
February 22, 2018: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/29457937/support-with-nutrition-for-women-receiving-chemotherapy-for-breast-cancer
#3
Fiona Gilmour, Anne Williams
Nurses are in a unique position to provide nutritional advice and information to women with breast cancer who are undergoing chemotherapy, supporting them with making decisions regarding nutrition and diet. This narrative review evaluated the research evidence relating to the nutritional challenges experienced during chemotherapy and the most effective approaches for supporting women in dietary choice. Weight gain was identified as a specific problem for women undergoing chemotherapy. The evidence indicated that information about nutrition and food preparation support may go some way in assisting women to overcome some of the nutrition-related difficulties experienced during chemotherapy treatment for breast cancer...
February 22, 2018: British Journal of Nursing: BJN
https://www.readbyqxmd.com/read/29456723/mir-96-promotes-breast-cancer-metastasis-by-suppressing-mtss1
#4
Wei Xie, Feng Sun, Lin Chen, Xinjian Cao
Novel, non-invasive biomarkers with high sensitivity and specificity are critical for breast cancer treatment, and prognosis. MicroRNA (miR)-96 has been demonstrated to be highly expressed in several solid malignancies, including breast cancer. However, its expression and function in the metastasis and prognosis of breast cancer have not been fully explored, and its regulation mechanisms remain unclear. In the present study, the serum miR-96 expression in healthy controls, benign and malignant breast cancer types was compared by using reverse transcription-quantitative polymerase chain reaction...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29456719/estrogen-receptor-%C3%AE-promoter-methylation-is-a-biomarker-for-outcome-prediction-of-cisplatin-resistance-in-triple-negative-breast-cancer
#5
Junnan Xu, Tao Sun, Xiangyu Guo, Yan Wang, Mingxi Jing
A number of previous studies have indicated the presence of a link between estrogen receptor-α (ERα) methylation and triple-negative breast cancer (TNBC). However, the association between ERα methylation and drug resistance during the treatment of TNBC remains unclear. Methylation-specific polymerase chain reaction was used to investigate the methylation of ERα in the genomic DNA of 35 patients with TNBC who were defined as cisplatin-based chemotherapy-resistant using chemosensitivity testing. Survival probabilities by covariates were assessed using Kaplan-Meier estimator survival analysis and Cox's proportional hazards models, adjusting for age, menopausal status, tumor size, lymph node metastasis and ERα promoter DNA methylation...
March 2018: Oncology Letters
https://www.readbyqxmd.com/read/29456703/silencing-of-tgif-sensitizes-mda-mb-231-human-breast-cancer-cells-to-cisplatin-induced-apoptosis
#6
Teng Pan, Tingting Mao, Haiyan Yang, Haiyu Wang, Yadong Wang
The present study was designed to explore the sensitivity of MDA-MB-231 cells to cisplatin after silencing the expression of TG-interacting factor (TGIF) protein. Cell viability was measured using an MTT assay. Cell apoptosis was detected by the annexin V and dead cell assay and the Hoechst staining assay. Protein expression was analyzed using western blot analysis. A colony formation assay was also performed. It was observed that cisplatin reduced the expression of TGIF protein in a dose- and time-dependent manner...
March 2018: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29456471/neoadjuvant-chemotherapy-exerts-selection-pressure-towards-luminal-phenotype-breast-cancer
#7
Giulia Galli, Giacomo Bregni, Stefano Cavalieri, Luca Porcu, Paolo Baili, Amash Hade, Francesca Di Salvo, Milena Sant, Roberto Agresti, Massimiliano Gennaro, Secondo Folli, Maria C De Santis, Biagio Paolini, Maria L Carcangiu, Filippo de Braud, Serena Di Cosimo
Background: Breast cancer (BC) phenotype after neoadjuvant chemotherapy (NAC) has not been extensively described and few data exist on whether expression of the primary tumor hormone receptors, HER2 and Ki-67 changes as a result of chemotherapy. Materials and Methods: We analyzed specimens from all BC patients treated with anthracycline/taxane-based NAC at our Institution between January 2010 and March 2015 (n = 325). The expression of estrogen receptor (ER), progesterone receptor (PR), HER2 and Ki-67 was determined in pre- and post-NAC specimens...
December 2017: Breast Care
https://www.readbyqxmd.com/read/29456109/synthetic-strigolactone-analogues-reveal-anti-cancer-activities-on-hepatocellular-carcinoma-cells
#8
Mohammed Nihal Hasan, Hani Choudhry, Syed Shoeb Razvi, Said Salama Moselhy, Taha Abduallah Kumosani, Mazin A Zamzami, Ziad Omran, Majed A Halwani, Salim Al-Babili, Khalid Omer Abualnaja, Abdulrahman Labeed Al-Malki, Mahmoud Alhosin, Tadao Asami
Hepatocellular carcinoma (HCC) remains one of the leading causes of death worldwide. The complex etiology is attributed to many factors like heredity, cirrhosis, hepatitis infections or the dysregulation of the different molecular pathways. Nevertheless, the current treatment regimens have either severe side effects or tumors gradually acquire resistance upon prolonged use. Thus, developing a new selective treatment for HCC is the need of the hour. Many anticancer agents derived from plants have been evaluated for their cytotoxicity towards many human cancer cell lines...
February 9, 2018: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/29455301/sexual-functioning-among-early-post-treatment-breast-cancer-survivors
#9
Nancy E Avis, Aimee Johnson, Mollie Rose Canzona, Beverly J Levine
PURPOSE: This study aims (1) to estimate percentages of partnered women who are sexually active over the first 2 years post-breast cancer diagnosis; (2) to identify factors related to sexual inactivity; and (3) to evaluate separately, among both sexually active and inactive survivors, the relation between sexual problems and treatment-related variables, symptoms, and psychosocial factors. METHODS: Longitudinal observational study of breast cancer survivors recruited within 8 months of cancer diagnosis and followed for 18 months...
February 17, 2018: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/29453736/reproductive-epidemiology-of-glial-tumors-may-reveal-novel-treatments-high-dose-progestins-or-progesterone-antagonists-as-endocrino-immune-modifiers-against-glioma
#10
REVIEW
Meric A Altinoz, Aysel Ozpinar, Ilhan Elmaci
Female gender, contraceptives, and menopausal hormone replacement treatments containing progesterone analogues associate with higher risk of meningiomas yet with lower risk of gliomas. Progesterone receptor (PR) expression and mifepristone treatment was highly discussed for meningiomas. However, much less is known in regard to progesterone actions in gliomas despite PR expression strongly correlates with their grade. Meningiomas and gliomas may grow faster during gestation; but paradoxically, parousity reduces lifetime risk of gliomas which can be explained with dichotomous cell growth-stimulating and inhibitory actions of progesterone at low versus high levels...
February 17, 2018: Neurosurgical Review
https://www.readbyqxmd.com/read/29452759/feasibility-study-of-weekly-nanoparticle-albumin-bound-paclitaxel-150-mg-m-2-followed-by-fluorouracil-epirubicin-and-cyclophosphamide-therapy-as-neoadjuvant-chemotherapy-for-her2-negative-breast-cancer
#11
Yasuyuki Kojima, Hisanori Kawamoto, Toru Nishikawa, Ryosuke Hayami, Arata Shimo, Ei Haku, Kyoko Akiyama, Koichiro Tsugawa
BACKGROUND: Although several studies have shown efficacy of nanoparticle albumin-bound (nab) paclitaxel use as a neoadjuvant treatment in breast cancer, dosage and schedules were varied or used in combination and the data are still limited for weekly regimens. We evaluated the feasibility of weekly nab-paclitaxel followed by FEC (5-FU [fluorouracil], epirubicin, and cyclophosphamide) treatment feasibility as neoadjuvant chemotherapy for breast cancer. PATIENTS AND METHODS: Thirty-three patients with no previous chemotherapy were enrolled to receive nab-paclitaxel 150 mg/m 2 the first 3 of 4 weeks (3q4w) followed by FEC as neoadjuvant treatment...
January 11, 2018: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29451059/-oncokompas-a-web-based-self-management-application-to-support-patient-activation-and-optimal-supportive-care-a-feasibility-study-among-breast-cancer-survivors
#12
Heleen C Melissant, Irma M Verdonck-de Leeuw, Birgit I Lissenberg-Witte, Inge R Konings, Pim Cuijpers, Cornelia F Van Uden-Kraan
BACKGROUND: Cancer survivors have to deal with symptoms related to cancer and its treatment. In Oncokompas, cancer survivors monitor their quality of life by completing patient reported outcome measures (PROMs), followed by personalized feedback, self-care advice, and supportive care options to stimulate patient activation. The aim of this study was to investigate feasibility and pretest-posttest differences of Oncokompas including a newly developed breast cancer (BC) module among BC survivors...
February 16, 2018: Acta Oncologica
https://www.readbyqxmd.com/read/29450753/use-of-breast-imaging-after-treatment-for-locoregional-breast-cancer-aft-01
#13
Taiwo Adesoye, Jessica R Schumacher, Heather B Neuman, Stephen Edge, Daniel McKellar, David P Winchester, Amanda B Francescatti, Caprice C Greenberg
BACKGROUND: Annual mammography is recommended after breast cancer treatment. However, studies suggest its under-utilization for Medicare patients. Utilization in the broader population is unknown, as is the role of breast magnetic resonance imaging (MRI). Understanding factors associated with imaging use is critical to improvement of adherence to recommendations. METHODS: A random sample of 9835 eligible patients receiving surgery for stages 2 and 3 breast cancer from 2006 to 2007 was selected from the National Cancer Database for primary data collection...
February 15, 2018: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/29450591/occurrence-of-pneumonitis-following-radiotherapy-of-breast-cancer-a-prospective-study
#14
Danijela Vasiljevic, Christoph Arnold, David Neuman, Katharina Fink, Marina Popovscaia, Irma Kvitsaridze, Meinhard Nevinny-Stickel, Markus Glatzer, Peter Lukas, Thomas Seppi
AIM: of this study is to determine the temporal resolution of therapy-induced pneumonitis, and to assess promoting factors in adjuvant treated patients with unilateral mammacarcinoma. PATIENTS AND METHODS: A total of 100 post-surgery patients were recruited. The cohort was treated by 2 field radiotherapy (2FRT; breast and chest wall, N = 75), 3 field radiotherapy (3FRT; + supraclavicular lymphatic region, N = 8), or with 4 field radiotherapy (4FRT; + parasternal lymphatic region, N = 17)...
February 15, 2018: Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft ... [et Al]
https://www.readbyqxmd.com/read/29450494/comparison-of-the-performance-of-6-prognostic-signatures-for-estrogen-receptor-positive-breast-cancer-a-secondary-analysis-of-a-randomized-clinical-trial
#15
Ivana Sestak, Richard Buus, Jack Cuzick, Peter Dubsky, Ralf Kronenwett, Carsten Denkert, Sean Ferree, Dennis Sgroi, Catherine Schnabel, Frederick L Baehner, Elizabeth Mallon, Mitch Dowsett
Importance: Multiple molecular signatures are available for managing estrogen receptor (ER)-positive breast cancer but with little direct comparative information to guide the patient's choice. Objective: To conduct a within-patient comparison of the prognostic value of 6 multigene signatures in women with early ER-positive breast cancer who received endocrine therapy for 5 years. Design, Setting, and Participants: This retrospective biomarker analysis included 774 postmenopausal women with ER-positive ERBB2 (formerly HER2)-negative breast cancer...
February 15, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29449898/targeted-therapy-of-brain-metastases-latest-evidence-and-clinical-implications
#16
REVIEW
Rodica Di Lorenzo, Manmeet S Ahluwalia
Brain metastases (BM) occur in 20-40% of patients with cancer and 60-75% of patients with BM become symptomatic. Due to an aging population and advances in the treatment of primary cancers, patients are living longer and are more likely to experience complications from BM. The diagnosis of BM drastically worsens long-term survival rates, with multiple metastases being a poor prognostic factor. Until recently, the mainstay of treatment consisted of stereotactic radiosurgery (SRS), surgical resection, whole brain radiation therapy (WBRT), or a combination of these modalities...
December 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29449692/the-deubiquitinase-usp9x-promotes-tumor-cell-survival-and-confers-chemoresistance-through-yap1-stabilization
#17
Lei Li, Tongzheng Liu, Yunhui Li, Chenming Wu, Kuntian Luo, Yujiao Yin, Yuping Chen, Somaira Nowsheen, Jinhuan Wu, Zhenkun Lou, Jian Yuan
The Yes-associated protein 1 (YAP1), a major downstream effector of the Hippo pathway, functions as a transcriptional regulator and has an important role in cellular control of organ size and tumor growth. Elevated oncogenic activity of YAP1 has been clarified in different types of human cancers, which contributes to cancer cell survival and chemoresistance. However, the molecular mechanism of YAP1 overexpression in cancer is still not clear. Here we demonstrate that the deubiquitination enzyme USP9X deubiquitinates and stabilizes YAP1, thereby promoting cancer cell survival...
February 16, 2018: Oncogene
https://www.readbyqxmd.com/read/29449123/early-impact-of-medicaid-expansion-and-quality-of-breast-cancer-care-in-kentucky
#18
Nicolas Ajkay, Neal Bhutiani, Bin Huang, Quan Chen, Jeffrey D Howard, Thomas C Tucker, Charles R Scoggins, Kelly M McMasters, Hiram C Polk
BACKGROUND: In January 2014, Kentucky expanded Medicaid coverage to include all individuals and families with incomes up to 33% above the federal poverty line. This study evaluated the early impact of Medicaid expansion on some aspects of the quality of breast cancer care in Kentucky. STUDY DESIGN: The Kentucky Cancer Registry was queried for all women aged 20 to 64 years diagnosed with breast cancer between 2011 and 2016. Demographic, tumor, and treatment characteristics were assessed for each year during this interval...
February 10, 2018: Journal of the American College of Surgeons
https://www.readbyqxmd.com/read/29448311/enhancing-decision-making-about-adjuvant-chemotherapy-in-early-breast-cancer-following-endopredict-testing
#19
Lesley Fallowfield, Lucy Matthews, Shirley May, Valerie Jenkins, David Bloomfield
Chemotherapy side-effects can be substantial. There is increasing recognition that some oestrogen receptor positive (ER+ve), human epidermal growth factor receptor 2 negative (HER2-ve) patients with breast cancer derive no benefit from chemotherapy and experience only iatrogenic harm. Gene expression profiling tests help refine recurrence risk and likely chemotherapy benefit. EndoPredict® is one such test, which classifies risks of distant recurrence as low or high in patients treated with surgery and adjuvant endocrine therapy alone...
February 15, 2018: Psycho-oncology
https://www.readbyqxmd.com/read/29448072/a-phase-iii-study-comparing-sb3-a-proposed-trastuzumab-biosimilar-and-trastuzumab-reference-product-in-her2-positive-early-breast-cancer-treated-with-neoadjuvant-adjuvant-treatment-final-safety-immunogenicity-and-survival-results
#20
X Pivot, I Bondarenko, Z Nowecki, M Dvorkin, E Trishkina, J-H Ahn, S-A Im, T Sarosiek, S Chatterjee, M Z Wojtukiewicz, Y Shparyk, V Moiseyenko, M Bello, V Semiglazov, Y Lee, J Lim
BACKGROUND: The equivalent efficacy between SB3, a proposed trastuzumab biosimilar, and the trastuzumab reference product (TRZ) in terms of the breast pathologic complete response rate after neoadjuvant therapy in patients with early or locally advanced human epidermal growth factor receptor 2-positive breast cancer was demonstrated in the previous report. Here, we report the final safety, immunogenicity and survival results after neoadjuvant-adjuvant treatment. PATIENTS AND METHODS: Patients were randomised 1:1 to receive neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide)...
February 12, 2018: European Journal of Cancer
keyword
keyword
40931
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"